Cite
HARVARD Citation
Soileau, M. et al. (2022). Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet neurology. 21 (12), pp. 1099-1109. [Online].